Mitapivat
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pyruvate Kinase Deficiency
Conditions
Pyruvate Kinase Deficiency
Trial Timeline
Mar 21, 2019 → Jul 3, 2024
NCT ID
NCT03853798About Mitapivat
Mitapivat is a phase 3 stage product being developed by Agios Pharmaceuticals for Pyruvate Kinase Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT03853798. Target conditions include Pyruvate Kinase Deficiency.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06286046 | Phase 2 | Recruiting |
| NCT07055243 | Phase 2 | Recruiting |
| NCT05777993 | Approved | Recruiting |
| NCT05610657 | Phase 1 | Completed |
| NCT05031780 | Phase 2/3 | Active |
| NCT03853798 | Phase 3 | Completed |
Competing Products
9 competing products in Pyruvate Kinase Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 1 | 28 |
| Mitapivat + Mitapivat-matching placebo | Agios Pharmaceuticals | Phase 3 | 72 |
| Mitapivat + Mitapivat-matching placebo | Agios Pharmaceuticals | Phase 3 | 72 |
| Placebo + AG-348 | Agios Pharmaceuticals | Phase 3 | 72 |
| Mitapivat | Agios Pharmaceuticals | Approved | 80 |
| AG-348 | Agios Pharmaceuticals | Phase 3 | 72 |
| AG-348 | Agios Pharmaceuticals | Phase 2 | 47 |
| RP-L301 | Rocket Pharmaceuticals | Phase 1 | 25 |
| RP-L301 | Rocket Pharmaceuticals | Phase 2 | 44 |